MicroRNA-382-5p Aggravates Breast Cancer Progression by Regulating the RERG/Ras/ERK Signaling Axis

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Oct 6

PMID 27705918

Citations 44

Authors

Jar-Yi Ho

Ren-Jun Hsu

Jui-Ming Liu

Szu-Chi Chen

Guo-Shiou Liao

Hong-Wei Gao

Cheng-Ping Yu

Affiliations

Soon will be listed here.

Abstract

Aberrant activation of the Ras/ERK pathway mediates breast cancer initiation and aggressiveness. Therefore, it is important to identify miRNAs that modulate the Ras/ERK pathway during breast carcinogenesis and progression. The Ras GTPase superfamily member RERG (Ras-related and estrogen-regulated growth inhibitor) acts as a tumor suppressor to reduce breast cancer cell proliferation and tumor formation and has been suggested to have a regulatory role in the Ras/ERK pathway. In this study, we found that RERG exerted its tumor suppressor role by attenuating the activation of Ras/ERK signaling effectors. Furthermore, we found that miR-382-5p directly targets and represses RERG to attenuate the inhibitory effects of RERG on the oncogenic Ras/ERK pathway. Thereby, miR-382-5p promoted breast cancer cell viability, clonogenicity, survival, migration, invasion and in vivo tumorigenesis/metastasis. In clinical interpretation, miR-382-5p expression was negatively correlated with RERG expression, and it also significantly functioned as an independent oncomiR for the higher incidence and poorer prognosis of breast cancer. This novel connection highlights new diagnostic and prognostic roles for miR-382-5p and RERG in breast cancer.

Citing Articles

Choice of blood collection methods influences extracellular vesicles counts and miRNA profiling.

Tran V, de Oliveira-Jr G, Chidester S, Lu S, Pleet M, Ivanov A J Extracell Biol. 2024; 3(10):e70008.

PMID: 39440167 PMC: 11494683. DOI: 10.1002/jex2.70008.

G2/M Checkpoint Modulation: Insights from miRNA Profiles in FAM and Breast Cancer.

Haryana S, Ardiansyah S, Noficandra H, Wardana T, Sesotyosari S, Arfira F Asian Pac J Cancer Prev. 2024; 25(8):2661-2668.

PMID: 39205563 PMC: 11495450. DOI: 10.31557/APJCP.2024.25.8.2661.

Unraveling Roles of miR-27b-3p as a Potential Biomarker for Breast Cancer in Malay Women via Bioinformatics Analysis.

Jusoh A, Al-Astani Bin Tengku Din T, Abdullah-Zawawi M, Wan Abdul Rahman W, Nafi S, Romli R Int J Mol Cell Med. 2024; 12(3):257-274.

PMID: 38751652 PMC: 11092903. DOI: 10.22088/IJMCM.BUMS.12.3.257.

Gene Variants in Clinicopathological Aspects and Prognosis of Patients with Cutaneous Melanoma.

Carvalho B, Gomez G, Carron J, Macedo L, Goncalves G, de Lima Vazquez V Int J Mol Sci. 2024; 25(5).

PMID: 38474115 PMC: 10932403. DOI: 10.3390/ijms25052868.

Exosomes-Promising Carriers for Regulatory Therapy in Oncology.

Jozwicka T, Erdmanska P, Stachowicz-Karpinska A, Olkiewicz M, Jozwicki W Cancers (Basel). 2024; 16(5).

PMID: 38473285 PMC: 10931160. DOI: 10.3390/cancers16050923.

References

Grubisha M, Cifuentes M, Hammes S, DeFranco D . A local paracrine and endocrine network involving TGFβ, Cox-2, ROS, and estrogen receptor β influences reactive stromal cell regulation of prostate cancer cell motility. Mol Endocrinol. 2012; 26(6):940-54. PMC: 3355541. DOI: 10.1210/me.2011-1371. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Haldosen L, Zhao C, Dahlman-Wright K . Estrogen receptor beta in breast cancer. Mol Cell Endocrinol. 2013; 382(1):665-672. DOI: 10.1016/j.mce.2013.08.005. View

Hsu R, Yang H, Tsai H . Labeled microRNA pull-down assay system: an experimental approach for high-throughput identification of microRNA-target mRNAs. Nucleic Acids Res. 2009; 37(10):e77. PMC: 2691847. DOI: 10.1093/nar/gkp274. View

Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

Masliah-Planchon J, Garinet S, Pasmant E . RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Oncotarget. 2015; 7(25):38892-38907. PMC: 5122439. DOI: 10.18632/oncotarget.6476. View

Omoto Y, Iwase H . Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects. Cancer Sci. 2015; 106(4):337-43. PMC: 4409875. DOI: 10.1111/cas.12613. View

Zhou B, Song J, Han T, Huang M, Jiang H, Qiao H . MiR-382 inhibits cell growth and invasion by targeting NR2F2 in colorectal cancer. Mol Carcinog. 2016; 55(12):2260-2267. DOI: 10.1002/mc.22466. View

Hemmatzadeh M, Mohammadi H, Jadidi-Niaragh F, Asghari F, Yousefi M . The role of oncomirs in the pathogenesis and treatment of breast cancer. Biomed Pharmacother. 2016; 78:129-139. DOI: 10.1016/j.biopha.2016.01.026. View

10.

Sivaraman V, Wang H, Nuovo G, Malbon C . Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest. 1997; 99(7):1478-83. PMC: 507966. DOI: 10.1172/JCI119309. View

11.

Thomas C, Gustafsson J . The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011; 11(8):597-608. DOI: 10.1038/nrc3093. View

12.

Wang L, Shi M, Hou S, Ding B, Liu L, Ji X . MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1. FEBS Lett. 2012; 586(9):1312-7. DOI: 10.1016/j.febslet.2012.03.035. View

13.

Monsivais D, Dyson M, Yin P, Coon J, Navarro A, Feng G . ERβ- and prostaglandin E2-regulated pathways integrate cell proliferation via Ras-like and estrogen-regulated growth inhibitor in endometriosis. Mol Endocrinol. 2014; 28(8):1304-15. PMC: 4116594. DOI: 10.1210/me.2013-1421. View

14.

Tan H, He Q, Gong G, Wang Y, Li J, Wang J . miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer. Int J Oncol. 2015; 48(1):181-90. DOI: 10.3892/ijo.2015.3241. View

15.

Jansson M, Lund A . MicroRNA and cancer. Mol Oncol. 2012; 6(6):590-610. PMC: 5528350. DOI: 10.1016/j.molonc.2012.09.006. View

16.

Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti C . ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell. 2010; 17(4):319-32. PMC: 2881822. DOI: 10.1016/j.ccr.2010.02.030. View

17.

Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U . Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer. 2000; 89(4):384-8. DOI: 10.1002/1097-0215(20000720)89:4<384::aid-ijc11>3.0.co;2-r. View

18.

Hoadley K, Weigman V, Fan C, Sawyer L, He X, Troester M . EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics. 2007; 8:258. PMC: 2014778. DOI: 10.1186/1471-2164-8-258. View

19.

Hayes J, Peruzzi P, Lawler S . MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014; 20(8):460-9. DOI: 10.1016/j.molmed.2014.06.005. View

20.

Zhao C, Putnik M, Gustafsson J, Dahlman-Wright K . Microarray analysis of altered gene expression in ERbeta-overexpressing HEK293 cells. Endocrine. 2009; 36(2):224-32. DOI: 10.1007/s12020-009-9233-8. View